Citatuzumab bogatox
Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models[1][2][3].
Product Specifications
CAS Number
945228-49-9
Product Name Alternative
VB6-845; Anti-Human EpCAM Recombinant Antibody Fab Fragment, 17-1A
UNSPSC
12352203
Target
Apoptosis
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
[Citatuzumabbogatox]
References & Citations
[1]Cizeau J, et al. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother. 2009 Jul-Aug;32 (6) :574-84. |[2]Eyvazi S, et al. Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update. Curr Cancer Drug Targets. 2018;18 (9) :857-868. |[3]Bruce VJ, et al. Minimalist Antibodies and Mimetics: An Update and Recent Applications. Chembiochem. 2016 Oct 17;17 (20) :1892-1899.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC682145-500 1x 500 µL
CD61 / Integrin 3 / Platelet Glycoprotein IIIa (Platelet Marker) (ITGB3/2145), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470950-500 1x 500 µL
MiTF (Microphthalmia Transcription Factor) (D5 + MITF/915), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401082-500 1x 500 µL
MHC II (HLA-DRA) (19-26.1), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details